Deutetrabenazine -A Review
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Veröffentlicht: |
Zenodo
2026
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866901088998785024 |
|---|---|
| author | Adavelli Rishitha*, Dr. M. Sunitha Reddy, Dr. K. Anie Vijetha |
| author_facet | Adavelli Rishitha*, Dr. M. Sunitha Reddy, Dr. K. Anie Vijetha |
| contents | <p><span lang="EN-GB">Deutetrabenazine is a recently approved therapy for the management of chorea in Huntington’s disease (HD) and represents the first deuterium-modified medication authorized by the U.S. Food and Drug Administration for clinical use. It is a vesicular monoamine transporter 2 (VMAT2) inhibitor and structurally similar to tetrabenazine, it is structurally derived from tetrabenazine, with selective substitution of deuterium atoms which prolongs its half-life and permits more stable plasma concentrations. This pharmacokinetic modification enables twice-daily dosing, up to a maximum of 48 mg per day, providing exposure comparable to higher daily doses of tetrabenazine.<span> </span>Deutetrabenazine demonstrated significant reductions in chorea severity. The treatment was generally well tolerated, with an adverse event profile similar to placebo. The indirect comparative analyses suggests that while both deutetrabenazine and tetrabenazine effectively reduce chorea, tetrabenazine may show a marginally greater side effects, whereas deutetrabenazine appears to have superior tolerability. However, these findings have not been confirmed in direct head-to-head trials.<span> </span>Overall, available data support deutetrabenazine as an effective and potentially better-tolerated option for the treatment of chorea in Huntington’s disease. Further comparative studies and long-term real-world data are needed to clarify its relative efficacy and safety profile.</span><span>.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_18898154 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Deutetrabenazine -A Review Adavelli Rishitha*, Dr. M. Sunitha Reddy, Dr. K. Anie Vijetha Deutetrabenazine, Huntington's disease, chorea, VMAT2 inhibitor, tetrabenazine <p><span lang="EN-GB">Deutetrabenazine is a recently approved therapy for the management of chorea in Huntington’s disease (HD) and represents the first deuterium-modified medication authorized by the U.S. Food and Drug Administration for clinical use. It is a vesicular monoamine transporter 2 (VMAT2) inhibitor and structurally similar to tetrabenazine, it is structurally derived from tetrabenazine, with selective substitution of deuterium atoms which prolongs its half-life and permits more stable plasma concentrations. This pharmacokinetic modification enables twice-daily dosing, up to a maximum of 48 mg per day, providing exposure comparable to higher daily doses of tetrabenazine.<span> </span>Deutetrabenazine demonstrated significant reductions in chorea severity. The treatment was generally well tolerated, with an adverse event profile similar to placebo. The indirect comparative analyses suggests that while both deutetrabenazine and tetrabenazine effectively reduce chorea, tetrabenazine may show a marginally greater side effects, whereas deutetrabenazine appears to have superior tolerability. However, these findings have not been confirmed in direct head-to-head trials.<span> </span>Overall, available data support deutetrabenazine as an effective and potentially better-tolerated option for the treatment of chorea in Huntington’s disease. Further comparative studies and long-term real-world data are needed to clarify its relative efficacy and safety profile.</span><span>.</span></p> |
| title | Deutetrabenazine -A Review |
| topic | Deutetrabenazine, Huntington's disease, chorea, VMAT2 inhibitor, tetrabenazine |
| url | https://doi.org/10.5281/zenodo.18898154 |